Martyna Giedrojc-Amir

Martyna Giedrojc-Amir is Regional Director of Value & Access for the Middle East and North Africa (MENA) at Danaher Diagnostics, based in Riyadh, Saudi Arabia, where she leads strategies to inform national guidelines, foster scientific consensus, and engage policymakers to improve uptake of innovative diagnostic solutions. Her responsibilities include shaping policy frameworks, developing tailored offerings for payers, and supporting local evidence generation development for better market access and adoption of Cepheid’s technologies across the region.

Prior to her current role, Martyna served as Senior Director of Government Affairs EMEA, where she accelerated market access strategies in the UK by engaging NHS, government, and patient stakeholders, by aligning policy with the economic clinical value of our solutions, and helped to establish global public -private partnerships on antimicrobial resistance (AMR). She originally joined Cepheid, a Danaher company, in 2021 as Director of Public Affairs Europe, where she worked on EU-level, contributing to the AMR Council Recommendation, and strengthening relationships with agencies such as EU HERA focused on pandemic preparedness.

Before joining Cepheid, Martyna worked in Brussels and London as a healthcare consultant for public c affairs agencies APCO Worldwide and RPP Group, advising global pharmaceutical and diagnostics companies on public affairs, policy shaping, and market access strategies. Her expertise spans public health, infectious diseases, antimicrobial resistance, and diagnostic & digital innovation.

Martyna holds a Master’s in Public Health & Healthcare Management from the Medical University of Warsaw. She is also completing a Diploma in Health Economics & Outcomes Research (HEOR) and Market Access in the MENA region with Saint Joseph University, Lebanon.

She is passionate about high-growth markets and unlocking untapped opportunities to advance healthcare policy and patient outcomes. Her expertise spans public health, infectious diseases, antimicrobial resistance, and digital & diagnostic innovation.